20 articles
A Lancet Healthy Longevity editorial calls for systemic elevation of cancer survivorship care as a public health and longevity priority.
A bespoke DNA vaccine tailored to individual glioblastoma tumors shows promising immunological activity in one of oncology's hardest challenges.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A phase 1 trial of a neoantigen DNA vaccine for glioblastoma found strong immune responses and survival rates exceeding historical benchmarks.
New molecular analysis tool could revolutionize treatment decisions for chronic myelomonocytic leukemia patients.
A Dana-Farber review maps the path for personalized cancer vaccines — pinpointing which tumors, timing, and combination strategies will matter most.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
New EUS techniques enable liquid biopsies, AI-assisted diagnosis, and personalized therapy testing for pancreatic and liver diseases.
New research reveals young and elderly cervical cancer patients have completely different molecular signatures requiring age-specific treatments.
Large study reveals cancer survivors have higher biological age than cancer-free individuals, with strongest mortality predictions from epigenetic clocks.
Scientists develop advanced drug delivery methods to detect and eliminate harmful senescent tumor cells that promote cancer spread.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
A comprehensive review reveals how combining genomics, proteomics, and metabolomics is uncovering new AML targets and improving patient outcomes.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
New targeted therapies and personalized treatments are transforming ovarian cancer care, offering hope for better outcomes and longer survival.
